PMC:7242013 / 11870-12046 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"356","span":{"begin":88,"end":96},"obj":"Species"},{"id":"367","span":{"begin":38,"end":46},"obj":"Disease"}],"attributes":[{"id":"A356","pred":"tao:has_database_id","subj":"356","obj":"Tax:9606"},{"id":"A367","pred":"tao:has_database_id","subj":"367","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ould be prioritized as candidates for COVID‐19 drug trials. EASL and AASLD mention that patients with NAFLD are more likely than others to have other comorbidity risks for seve"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T143","span":{"begin":38,"end":46},"obj":"Disease"}],"attributes":[{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ould be prioritized as candidates for COVID‐19 drug trials. EASL and AASLD mention that patients with NAFLD are more likely than others to have other comorbidity risks for seve"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T46","span":{"begin":47,"end":51},"obj":"Chemical"}],"attributes":[{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"ould be prioritized as candidates for COVID‐19 drug trials. EASL and AASLD mention that patients with NAFLD are more likely than others to have other comorbidity risks for seve"}